European review for medical and pharmacological sciences最新文献

{"title":"Expression of Concern on \"A deep learning algorithm-based visual strategy intervention study for children with autism spectrum disorders - extraction and detection of children's behavioral features\".","authors":"","doi":"10.26355/eurrev_202603_37714","DOIUrl":"10.26355/eurrev_202603_37714","url":null,"abstract":"<p><p>The Editor in Chief and the Publisher are issuing an expression of concern regarding the following article: Lin Y. A deep learning algorithm-based visual strategy intervention study for children with autism spectrum disorders - extraction and detection of children's behavioral features. Eur Rev Med Pharmacol Sci 2023; 27 (11): 4914-4928-DOI: 10.26355/eurrev_202306_32608-PMID: 37318465. Following third-party notification raising concerns about the relevance of some references cited in the manuscript, the journal initiated an editorial review of the article. This review identified that several references appear unrelated to the context in which they are cited. The authors were contacted on multiple occasions and invited to provide clarification; however, no response has been received to date. In accordance with the journal's editorial policies and the Committee on Publication Ethics (COPE) guidelines, the Editors are issuing this Expression of Concern to alert readers while the matter remains unresolved. The journal will update the record if further information becomes available. The Publisher apologizes for any inconvenience this may cause.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 3","pages":"92"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: LncRNA MEG3 inhibits proliferation and promotes apoptosis of synovial cells in rats with knee osteoarthritis by regulating PTEN.","authors":"K Han, F-R Wang, M-Q Yu, B Xu","doi":"10.26355/eurrev_202603_37718","DOIUrl":"https://doi.org/10.26355/eurrev_202603_37718","url":null,"abstract":"<p><p>The article \"LncRNA MEG3 inhibits proliferation and promotes apoptosis of synovial cells in rats with knee osteoarthritis by regulating PTEN\" by K. Han, F.-R. Wang, M.-Q. Yu, B. Xu, published in Eur Rev Med Pharmacol Sci 2020; 24 (10): 5242-5248-DOI: 10.26355/eurrev_202005_21306-PMID: 32495857, has been retracted by the Publisher and the Editor in Chief, following a previously published Expression of Concern. As previously reported, concerns were raised regarding the reliability and originality of the data. The journal has continued its assessment of the article. In the course of this process, additional concerns have been identified, including multiple instances of apparent duplication of image panels (notably flow cytometry plots) between this article and other published articles. In light of these circumstances, the Publisher and the Editor in Chief have decided to retract this article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 3","pages":"95"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with hypoxia and severity in patients with both obstructive sleep apnea syndrome and chronic obstructive pulmonary disease.","authors":"M A Vultur, A M Inchingolo, I R Bordea, D Huțanu, L Ferrante, F Inchingolo, A D Inchingolo, G Dipalma, G Jimborean","doi":"10.26355/eurrev_202603_37719","DOIUrl":"https://doi.org/10.26355/eurrev_202603_37719","url":null,"abstract":"<p><strong>Objective: </strong>The frequent co-occurrence of obstructive sleep apnea syndrome (OSAS) and chronic obstructive pulmonary disease (COPD) gives rise to an overlap syndrome associated with a decline in patients' health. Discerning the nuanced clinical presentations, polygraphy data, and hematological profiles of individuals with isolated OSAS from those with comorbid OSAS and COPD is crucial for tailoring effective therapeutic strategies. The present investigation seeks to delineate the demographic, clinical, polygraphy, and hematological features that differentiate patients with OSAS alone from those with concurrent OSAS and COPD, and further to evaluate the independent predictive value of COPD for OSAS severity.</p><p><strong>Materials and methods: </strong>In this cross-sectional analysis, 68 adults diagnosed with OSAS by overnight polygraphy were classified into two groups: OSAS-only (n = 49) and OSAS plus COPD (overlap syndrome, n = 19). Collected data encompassed demographics, comorbidities, sleep indices [including apnea-hypopnea index (AHI), oxygen desaturation index (ODI), and percentage of sleep time with oxygen saturation &lt; 90% (t90%)], and routine hematological examinations. Group comparisons used appropriate statistical tests, and multivariable logistic regression evaluated predictors of severe OSAS.</p><p><strong>Results: </strong>Compared with patients who had OSAS alone, those with overlap syndrome exhibited more severe sleep-disordered breathing and nocturnal desaturation: median AHI was higher (55.80 vs. 38.06; p = 0.01), ODI was increased (57.50 vs. 41.10; p = 0.03), and t90% was longer (32.20% vs. 19.00%; p = 0.03). Mean corpuscular volume (MCV) was also greater in the COPD group (p = 0.01). While COPD showed a trend toward being associated with severe OSAS (odds ratio 2.18), this association did not reach statistical significance (p = 0.36). Hypertension was more prevalent among patients with overlap syndrome and can suggest an elevated cardiovascular risk in this subgroup.</p><p><strong>Conclusions: </strong>The convergence of COPD and OSAS correlates with severe sleep apnea, intensified nocturnal hypoxemia, and an increased prevalence of hypertension, thereby highlighting the imperative for meticulous evaluation and personalized treatment paradigms in this patient population. Limitations inherent in this study, specifically the constrained sample size and cross-sectional methodology, necessitate circumspect interpretation of the findings and suggest the value of prospective, large-scale investigations to corroborate these observations.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 3","pages":"96-104"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological enhancement of tissue expansion for breast reconstruction.","authors":"E Bertulla, E Raposio","doi":"10.26355/eurrev_202603_37720","DOIUrl":"https://doi.org/10.26355/eurrev_202603_37720","url":null,"abstract":"<p><p>Tissue expander-based breast reconstruction is widely used following mastectomy due to its relative technical simplicity, minimal additional anesthesia, and reversibility. However, complications such as tissue necrosis, impaired vascularity, postoperative pain, and infections are frequent. Pharmacological interventions have been explored to improve tissue viability and reduce these complications. A literature search was performed in PubMed, Scopus, and Cochrane Library, focusing on clinical and preclinical studies investigating pharmacologic agents applied topically or systemically in tissue expander breast reconstruction. Studies on autologous reconstruction, direct-to-implant procedures, cosmetic surgeries, systemic antibiotic prophylaxis, or unrelated drug effects were excluded. Eight studies met the inclusion criteria, including retrospective cohort studies, prospective trials, randomized controlled trials, and preclinical investigations. Agents examined included botulinum toxin, deferoxamine, nitroglycerine, dimethyl sulfoxide, and local antibiotics [absorbable beads or polymethyl methacrylate (PMMA) disks]. Botulinum toxin showed limited evidence for postoperative pain reduction. Deferoxamine increased vascularity and tissue elasticity, especially in irradiated tissue. Nitroglycerine paste reduced mastectomy flap necrosis. Topical Dimethyl sulfoxide (DMSO) improved expansion dynamics and dermal collagen architecture. Local antibiotic delivery significantly decreased infection rates and expander loss, including in patients with skin necrosis. Overall, pharmacological strategies demonstrate potential to enhance tissue viability, minimize complications, and optimize outcomes in tissue expander-based breast reconstruction. Local antibiotic prophylaxis, topical agents, and vascular modulators appear particularly promising. Nevertheless, evidence remains limited by small sample sizes, heterogeneity of study designs, and the inclusion of some preclinical data. Further prospective, controlled trials are warranted to standardize protocols, confirm safety, and evaluate long-term clinical efficacy.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 3","pages":"105-112"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Simultaneous administration of human acidic and recombinant less acidic follicle-stimulating hormone for ovarian stimulation improves oocyte and embryo quality, and clinical outcome in patients with repeated IVF failures.","authors":"H Selman, A Pacchiarotti, L Rinaldi, F Crescenzi, G Lanzilotti, S Lofino, I El-Danasouri","doi":"10.26355/eurrev_202603_37716","DOIUrl":"https://doi.org/10.26355/eurrev_202603_37716","url":null,"abstract":"<p><p>The article \"Simultaneous administration of human acidic and recombinant less acidic follicle-stimulating hormone for ovarian stimulation improves oocyte and embryo quality, and clinical outcome in patients with repeated IVF failures\" by H. Selman, A. Pacchiarotti, L. Rinaldi, F. Crescenzi, G. Lanzilotti, S. Lofino, I. El-Danasouri, published Eur Rev Med Pharmacol Sci 2013; 17 (13): 1814-1819-PMID: 23852909, has been retracted by the Publisher and the Editor in Chief. Following concerns raised about similarities between the data reported in this article and those published in a previous article by overlapping author groups, the journal initiated an editorial investigation. The journal contacted the authors requesting clarification and the underlying dataset supporting the reported results. The requested data were never supplied despite multiple follow-up requests from the editorial office. The journal's investigation identified substantial similarities in the data reported in the Table I between this article and a previously published work. In the absence of the original dataset and given the unresolved concerns, the Editor-in-Chief has concluded that the reliability of the results reported in this article cannot be verified. Therefore, the article is retracted. This article has been retracted. The Publisher apologizes for any inconvenience this may cause.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 3","pages":"93"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Preclinical study of vitamin D deficiency in the pathogenesis of metabolic syndrome in rats.","authors":"S K Mahjoub, M A A Sattar Ahmad, F O Kamel, M Alseini, L M Khan","doi":"10.26355/eurrev_202602_37683","DOIUrl":"https://doi.org/10.26355/eurrev_202602_37683","url":null,"abstract":"<p><p>The article \"Preclinical study of vitamin D deficiency in the pathogenesis of metabolic syndrome in rats\" by S.K. Mahjoub, M.A.A. Sattar Ahmad, F.O. Kamel, M. Alseini, L.M. Khan published in Eur Rev Med Pharmacol Sci 2022; 26 (23): 9001-9014-DOI: 10.26355/eurrev_202212_30575-PMID: 36524519 has been retracted in accordance with the Publisher and the Editor in Chief. Following the publication of the above-mentioned article, concerns were raised by a whistleblower and on PubPeer regarding multiple concerns affecting the reliability of the reported data. The journal contacted the corresponding author on multiple occasions and formally requested clarification and access to the original raw data supporting the published results. Despite repeated attempts, no response or supporting documentation was received. In accordance with COPE guidance, the journal conducted an independent assessment of the published material. This evaluation identified major methodological and analytical deficiencies and confirmed the concerns raised. On the basis of the available information, the reliability of the findings could not be verified and the conclusions of the study cannot be confirmed. Therefore, the article is retracted. The authors have been informed of this decision and have not responded. This article has been retracted. The Publisher apologizes for any further inconvenience this may cause.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 2","pages":"52"},"PeriodicalIF":3.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-linked carboxymethyl cellulose and silk proteins for dry eye disease management and corneal wound healing: in vivo and in vitro results.","authors":"F Scarinci, G De Simone, G Coco, C Caggiano, G Pocobelli, F Boselli, A Di Masi","doi":"10.26355/eurrev_202602_37688","DOIUrl":"10.26355/eurrev_202602_37688","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective cohort study aims to uncover the potential clinical effectiveness of a novel ophthalmic solution containing cross-linked carboxymethyl cellulose (CX-CMC) and silk proteins (SP) in dry eye disease, evaluating its efficacy in improving Tear Breakup Time (TBUT) and Ocular Surface Disease Index (OSDI) over a 3-months treatment and in absorbing ultraviolet (UV) and blue light and promoting wound healing.</p><p><strong>Materials and methods: </strong>Two different populations were retrieved from the database; the first group consisted of 20 dry-eye patients who underwent a 3-month treatment with an ophthalmic solution containing CX-CMC and SP. The second group was composed of 10 dry-eye patients who did not want to use any eye lubricant or other treatment. The outcome measures, TBUT and OSDI, were analyzed before (T0) and after (T3) treatment. In addition, the ophthalmic solution was investigated for its capacity to absorb UV and blue light and to promote wound healing. Specifically, UV and blue absorbance were tested by means of a UV-VIS spectrophotometer, while the wound healing test was conducted using two distinct cell lines to assess the efficacy of the solution in facilitating cicatrization.</p><p><strong>Results: </strong>The ophthalmic solution effectively restored tear film stability, as evidenced by the improved TBUT values and reduced dry eye disease symptoms evaluated through the OSDI score. Furthermore, it demonstrated absorption capabilities within the UV and blue wavelength range. In terms of wound recovery, the ophthalmic solution supported cell motility compared to untreated cells.</p><p><strong>Conclusions: </strong>The ophthalmic solution containing CX-CMC and SP was effective in improving dry-eye signs and symptoms in patients and in absorbing UV and blue light. Furthermore, the ophthalmic solution promoted wound healing in vitro. Collectively, the results suggest that CX-CMC and SP eye drops could serve as a promising tool for treating dry eye disease of various origins.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 2","pages":"62-70"},"PeriodicalIF":3.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal dexamethasone implant in epiretinal membrane-associated diabetic macular edema refractory to anti-VEGF therapy: a visual performance and retinal ultra-structural analysis.","authors":"S Nalcaci, H H Gobeka, K Sincar, C Akkin, F Afrashi","doi":"10.26355/eurrev_202602_37689","DOIUrl":"10.26355/eurrev_202602_37689","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to report clinical outcomes of intravitreal dexamethasone (DEX) implant in patients with epiretinal membrane (ERM)-associated diabetic macular edema (DME) unresponsive to intravitreal ranibizumab (IVR).</p><p><strong>Materials and methods: </strong>11 eyes of type 2 diabetes patients &gt;18 years old with ERM-associated DME unresponsive to ≥3 IVR injections were included. Patients with central macular thickness (CMT) &gt;300 µm following a single dose DEX implant between January 2021 and December 2023, suggesting unresponsiveness or poor response, were retrospectively evaluated. A full ophthalmologic examination was performed pre- and first-to-sixth month post-therapy, including measuring best-corrected visual acuity (BCVA), intraocular pressure (IOP), and retinal ultra-structural parameters like CMT, central 1 mm retinal thickness (RT), and central macular volume (CMV).</p><p><strong>Results: </strong>The mean age was 66.50±5.01 years. BCVA increased considerably in the first two months (p&lt;0.050) compared to pre-therapy. Changes in CMT, RT, and CMV were statistically significant for ≥4 months for CMT, five months for RT, and six months for CMV (p&lt;0.050). Increased BCVA coincided with retinal ultra-structural healing throughout the same period. Most patients had predominantly normal IOPs. Anti-glaucoma medication was initiated in just three patients where IOPs were &gt;25 mmHg.</p><p><strong>Conclusions: </strong>DEX implant could be a reliable and effective therapeutic alternative for ERM-associated DME resistant to anti-VEGFs, particularly during the first 3 months of treatment, when it appears to be most effective. A single DEX implant can produce a satisfactory and reasonably safe response, and the treatment can be repeated even after the implant's potency has gradually declined. Importantly, improved BCVA and retinal ultra-structure following DEX implant could lessen the need for ERM surgery and multiple intravitreal anti-VEGF injections. If ERM-associated DME persists despite multiple DEX implants, surgery should be considered.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 2","pages":"71-82"},"PeriodicalIF":3.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chloroprocaine vs. prilocaine for spinal anesthesia in outpatient knee arthroscopy: a prospective economic evaluation using activity-based costing.","authors":"C Franceschi, F Tasso, V Simili, G Monteleone, F Martorelli, A De Angelis, E Cialdella, D Esposito, G Anzillotti, P Conte, B Di Matteo, E Kon, M Scardino","doi":"10.26355/eurrev_202602_37690","DOIUrl":"10.26355/eurrev_202602_37690","url":null,"abstract":"<p><strong>Objective: </strong>In orthopedic day-hospital interventions like knee arthroscopy, the choice of the short-acting local anesthetic to be used for spinal anesthesia may significantly impact both recovery times and hospital-related costs.</p><p><strong>Materials and methods: </strong>This prospective, two-arm cohort study included 70 adult patients undergoing an elective knee arthroscopy for meniscectomy who received either spinal chloroprocaine (40 mg, 1%) or prilocaine (40 mg, 2%). Cost analysis was performed using an activity-based costing approach, whereby resource utilization was multiplied by corresponding unit tariffs and summed across the following cost domains: operating room time, recovery room time, nurse care time, physician (anesthesiologist) care time, drug and device usage, and any unplanned overnight hospitalization. The primary outcome was the mean procedure cost per patient; secondary outcomes included perioperative time metrics and adverse events.</p><p><strong>Results: </strong>Seventy subjects were recruited and assigned to one of the two groups, each consisting of 35 patients. The mean cost of the procedure per patient was €604.76 in the chloroprocaine group vs. €938.09 in the prilocaine group (difference = €333.33). Recovery room time and physician (anesthesiologist) care time were significantly shorter in the chloroprocaine group compared to the prilocaine group (45.63 vs. 104.00 minutes and 57.86 vs. 100.57 minutes, respectively, both p-values &lt; 0.001). Urinary retention occurred in five patients in the prilocaine group, compared to none in the chloroprocaine group. One patient in the prilocaine group required overnight hospitalization.</p><p><strong>Conclusions: </strong>The use of chloroprocaine for spinal anesthesia was associated with significantly shorter perioperative care times and lower hospital-related costs compared to prilocaine. Nonetheless, further high-quality, multicenter randomized controlled trials are needed to confirm the pharmacoeconomic advantages of using chloroprocaine for cost-effective spinal anesthesia.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 2","pages":"83-90"},"PeriodicalIF":3.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of a novel bone bioactive oral rinse (Theravex) on early soft-tissue wound healing following simple tooth extraction in patients with type 2 diabetes mellitus: A prospective comparative clinical study.","authors":"A Almarghlani, A Kutbi, G Moumena, A Bokhari, W Ibraheem, R Sharka, H Abed","doi":"10.26355/eurrev_202602_37687","DOIUrl":"10.26355/eurrev_202602_37687","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to assess the effectiveness of bone bioactive rinse in promoting early wound healing following simple tooth extraction in diabetic patients.</p><p><strong>Materials and methods: </strong>A prospective comparative study was conducted at King Abdulaziz University Dental Hospital between March and May 2025. The study included 48 diabetic patients undergoing simple tooth extractions. Patients were assigned to either a test group (n=28) that used a bone bioactive rinse or a control group (n=20) that received no intervention. Healing was assessed on days 5 and 14 using a modified Early Healing Index (scale 1-5).</p><p><strong>Results: </strong>A total of 48 diabetic patients (mean age: 51.25 ± 11.8 years) were enrolled into the bone bioactive rinse group (n=28) and the control group (n=20). While socket dimension measurements (width, height, area) were not significantly different between groups at either day 5 or 2 weeks post-extraction (p &gt; 0.05), the clinical healing index showed a marked difference. On day 5, 96.4% of patients in the rinse group achieved a 'very good' healing score, compared to only 5% in the control group (p &lt; 0.001). By week 2, 100% of the test group maintained high healing scores, vs. 20% in the control group (p &lt; 0.001). No significant gender-related differences in healing outcomes were observed (p &gt; 0.3).</p><p><strong>Conclusions: </strong>Bone bioactive rinse significantly enhances early wound healing after tooth extraction in diabetic patients and may serve as a valuable adjunct in clinical practice.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 2","pages":"53-61"},"PeriodicalIF":3.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}